Neural Regeneration Research ›› 2020, Vol. 15 ›› Issue (12): 2235-2236.doi: 10.4103/1673-5374.284982

Previous Articles     Next Articles

Engineering mesenchymal stromal/ stem cell-derived extracellular vesicles with improved targeting and therapeutic efficiency for the treatment of central nervous system disorders

Alexandra M. Iavorovschi1, Aijun Wang1,2   

  1. 1 Surgical Bioengineering Laboratory, Department of Surgery, School of Medicine, University of California-Davis; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children-Northern California, Sacramento, CA, USA 2 Department of Biomedical Engineering, University of California, Davis School of Engineering, Davis, CA, USA 
  • Online:2020-12-15 Published:2020-08-04
  • Contact: Aijun Wang, PhD, aawang@ucdavis.edu.
  • Supported by:
    This work was in part supported by Shriner’s Hospital for Children (85108-NCA-19) and the NIH (5R01NS100761).

PDF

137

Abstract: Treatment for central nervous system (CNS) disorders is known to be limited by the low regenerative potential of neurons, and thus neurodegenerative insults became known as nearly irreversible ailments. Functional recovery for acquired CNS disorders, such as spinal cord injury (SCI), traumatic brain injury, ischemic stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), and for congenital CNS abnormalities, such as spina bifida, is not spontaneous and effective treatments are limited to non-existent.